Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

Background Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, limited data support its use in cancer patients. Objectives The primary outcome was major bleeding. Secondary out...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of thrombosis and haemostasis Vol. 18; no. 2; pp. 411 - 421
Main Authors:	McBane, Robert D., Wysokinski, Waldemar E., Le‐Rademacher, Jennifer G., Zemla, Tyler, Ashrani, Aneel, Tafur, Alfonso, Perepu, Usha, Anderson, Daniel, Gundabolu, Krishna, Kuzma, Charles, Perez Botero, Juliana, Leon Ferre, Roberto A., Henkin, Stanislav, Lenz, Charles J., Houghton, Damon E., Vishnu, Prakash, Loprinzi, Charles L.
Format:	Journal Article
Language:	English
Published:	England Elsevier Limited 01.02.2020
Subjects:	Anticoagulants Anticoagulants - adverse effects apixaban Bleeding Cancer Chemotherapy dalteparin Dalteparin - adverse effects Heparin Humans Malignancy Metastases Neoplasm Recurrence, Local Pyrazoles Pyridones Thromboembolism Treatment Outcome venous thromboembolism Venous Thromboembolism - diagnosis Venous Thromboembolism - drug therapy cancer bleeding apixaban venous thromboembolism dalteparin
ISSN:	1538-7933, 1538-7836, 1538-7836
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!